Modality
Multispecific
MOA
HPK1i
Target
SOS1
Pathway
STING
RCCCrohn's
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
~Aug 2019
→ ~Nov 2020
Phase 2
Feb 2021
→ Aug 2026
Phase 2Current
NCT03666989
1,703 pts·RCC
2021-02→2026-08·Active
1,703 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-285mo awayPh2 Data· RCC
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2
Active
Catalysts
Ph2 Data
2026-08-28 · 5mo away
RCC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03666989 | Phase 2 | RCC | Active | 1703 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 |